Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2018 | 2017 | 2015
Number of items: 3.


Doebele, R., Ahn, M., Siena, S., Drilon, A., Krebs, M., Lin, C., De Braud, F., John, T., Tan, D., Seto, T., Dziadziuszko, R., Arkenau, H., Barlesi, F., Rolfo, C., Wolf, J., Chow-Maneval, E., Multani, P., Cui, N., Riehl, T. and Cho, B. C. (2018). Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 13 (10). S. S321 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380


Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D., Garon, E., Groen, H., Hochmair, M., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S2399 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380


Wolf, J., Hochmair, M., Kattan, J. G., Ang, M. -K., Garon, E. B., Groen, H. J. M., Heist, R., Ohashi, K., Felip, E., Reguart, N., Garcia Campelo, R., Soo, R., Paz-Ares, L., de Marinis, F., Smit, E. F., Giovannini, M., Squires, M., Cui, X., Zhang, Y. and Tan, D. (2015). A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Ann. Oncol., 26. S. 146 - 147. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Thu Dec 2 06:12:51 2021 CET.